Merck & Co., Inc. (MRK)
What changed in recent filings
- Revenue +5% YoYQuarter ended Jun 30, 2026
- Institutions — 2 new · 1 added · 2 reduced13F · as of end of 2026 Q2
What changed in recent SEC filings — factual, not a buy/sell recommendation.
Merck & Co., Inc. recent earnings releases
Based on SEC filings. The release date is the day the earnings filing (8-K) was accepted; for quarters where that filing was not found, the periodic report filing date is shown.
- 26Q2Released Aug 4, 2026Revenue +5.1% YoY · EPS $-0.54Released before the open: Aug 3 close → Aug 4 close, the stock moved +0.2% · over the same window, market +1.8% · sector -0.2%
- 26Q1Released Apr 30, 2026Revenue +4.9% YoY · EPS $-1.72Released before the open: Apr 29 close → Apr 30 close, the stock moved -1.6% · over the same window, market +1.0% · sector +1.0%
- 25Q4Released Feb 3, 2026Revenue +5.0% YoY · EPS $1.20Released before the open: Feb 2 close → Feb 3 close, the stock moved +2.2% · over the same window, market -0.8% · sector -0.8%
- 25Q3Released Oct 30, 2025Revenue +3.7% YoY · EPS $2.32Released before the open: Oct 29 close → Oct 30 close, the stock moved -0.3% · over the same window, market -1.1% · sector +0.0%
The next earnings release is estimated around Oct 29, 2026 (calculated from how long this company has taken between quarter end and filing; it is not a date announced by the company).
Institutions holding Merck & Co., Inc.
How many of the institutions we track reported holding this stock, quarter by quarter.
2019 Q1: 7 → 2026 Q2: 10 institutions
Counts the 52 institutions we track that reported holding this stock — their full reported holdings, not just the largest positions. Not the total number of institutional holders in the US. Figures are as of quarter-end and disclosed up to 45 days later. Descriptive only — not investment advice.
Which institutions hold Merck & Co., Inc.
Institutions we track that reported holding this stock in their most recent 13F.
- National Pension Service (Korea)0.48% of portfolio · held as of 2019 Q1 or earlier
- Dodge & Cox0.01% of portfolio · held as of 2019 Q1 or earlier
- PRIMECAP Managementunder 0.01% of portfolio · held as of 2019 Q1 or earlier
- Caisse de depot (Quebec)0.81% of portfolio · held as of 2019 Q1 or earlier
- GQG Partners0.01% of portfolio · since 2021 Q1
- Harris Associates (Oakmark)2.06% of portfolio · since 2024 Q3
- Point72 Asset Management0.05% of portfolio · since 2025 Q2
- Pzena Investment Managementunder 0.01% of portfolio · since 2025 Q2
- Bridgewater AssociatesNew this quarter0.02% of portfolio · since 2026 Q2
- Temasek Holdings (Singapore)New this quarter0.28% of portfolio · since 2026 Q2
Based on 13F filings — quarter-end holdings, disclosed up to 45 days later. Holding a stock is a fact we report, not a recommendation to buy or sell.
Q2 2026 13F recap — stocks several institutions bought and sold together →Company overview
A pharma company where the immuno-oncology drug Keytruda accounts for over 40% of total revenue. Building out the pipeline to prepare for Keytruda's patent expiry is its challenge.
What is the Biotech & Health sector?
Pharma, biotech, and medical devices. Driven by trial-result events.
Merck & Co., Inc. is classified under the Biotech & Health sector. See peers below.
Merck & Co., Inc. key financials
Based on SEC filings · as of Jun 30, 2026
Tap a metric name to see its meaning in the glossary.
Merck & Co., Inc. vs Biotech & Health sector benchmark
Median of 38 representative sector stocks · SEC filings · factual comparison (not advice)
A simple comparison to the sector benchmark. Higher or lower doesn’t mean good/bad or buy/sell.
MRK revenue by segment summary
SEC 10-Q · segment totals cross-checked against total revenue
2026-06-30 revenue was $16.6B, +5.1% YoY.
The largest segment is Pharmaceutical, 89.3% of revenue — a highly concentrated structure.
Recent revenue growth was led mainly by the Pharmaceutical segment (about 89% of the increase).
Full segment weights, YoY changes, and an AI synthesis are available in the detailed analysis.
ETFs holding Merck & Co., Inc.
Per SEC N-PORT · 2026-06-30 · by weight · factual
MRK on Stocklore
- Revenue by segment — segment weights verified from SEC filings, YoY changes, growth drivers and concentration
- Financials & earnings quality — 6 metrics (FCF conversion, ROIC, net debt, etc.) to gauge profit quality
- 13F institutional holdings — holdings and weight changes of major institutions (45-day delay)
- Sector-relative metrics — Valuation and growth compared with the Biotech & Health average
Peers · Biotech & Health
MRK FAQ
What is Merck & Co., Inc. (MRK)?
A pharma company where the immuno-oncology drug Keytruda accounts for over 40% of total revenue. Building out the pipeline to prepare for Keytruda's patent expiry is its challenge.
What sector is Merck & Co., Inc. in?
Merck & Co., Inc. is classified under Biotech & Health. Pharma, biotech, and medical devices. Driven by trial-result events.
What are Merck & Co., Inc.'s key financials?
As of Jun 30, 2026 in SEC filings: Revenue growth (YoY) 4.6%, Net margin 4.8%, ROE 34.7%, Debt-to-equity 1.22x. Definitions and interpretation are available on Stocklore.
What are Merck & Co., Inc.'s main revenue segments?
The largest segment is Pharmaceutical, about 89.3% of revenue. Segment totals are cross-checked against total revenue from SEC filings.
Where can I analyze Merck & Co., Inc. (MRK) stock?
On Stocklore you can see MRK's financials & earnings quality, 13F institutional holdings, and sector-relative metrics in one place. This page is for information and tools — not a buy/sell recommendation.
Data sources: SEC EDGAR (financials & filings), 13F (institutional holdings, as of quarter-end), market data. This page is for information and analysis tools — it does not recommend buying or selling any security. Investment decisions and responsibility are your own.